Comparative Pharmacology
Head-to-head clinical analysis: CASODEX versus EULEXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASODEX versus EULEXIN.
CASODEX vs EULEXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the action of androgens by binding to cytosolic androgen receptors in target tissues, thereby blocking androgen-mediated gene expression and tumor growth. Does not suppress androgen production.
Nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to androgen receptors in target tissues, thereby blocking androgen action.
50 mg orally once daily
250 mg orally three times daily (every 8 hours).
None Documented
None Documented
Terminal elimination half-life: 5-7 days (steady-state achieved in ~4 weeks); Long half-life due to high protein binding and slow tissue redistribution
5-6 hours for flutamide; 8-10 hours for active metabolite 2-hydroxyflutamide; requires three times daily dosing
Renal: <1% as unchanged drug; Fecal: ~83% as metabolites (mostly glucuronide conjugates); Biliary: significant as metabolites; Total clearance: 0.42 mL/min/kg
Renal: 28% (as unchanged drug and metabolites, mainly 2-hydroxyflutamide), Biliary/Fecal: 4.2% (as metabolites)
Category C
Category C
Antiandrogen
Antiandrogen